Scarica l'app Stockscreener
5.28
4.76%
0.24
Pre-mercato:
5.28
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Savara Inc Borsa (SVRA) Ultime notizie
Aug Update: Whats the fair value of Savara Inc stockMarket Growth Review & Verified Swing Trading Watchlist - baoquankhu1.vn
Savara (SVRA) to Release Earnings on Tuesday - MarketBeat
Savara’s MOLBREEVI BLA Receives FDA Priority Review - MSN
Savara reports 2025 results, advances MOLBREEVI toward approval - MSN
FDA to review Savara resubmitted Molbreevi BLA - MSN
Savara Reports 2025 Results, Advances MOLBREEVI Toward Approval - MyChesCo
Savara Inc devrait afficher une perte de 12 cents par actionEarnings AVANT-PAPIER - TradingView
Aug Big Picture: What is the Moat Score of Savara IncNew Guidance & Stock Market Timing Techniques - baoquankhu1.vn
Savara (SVRA) CFO exercises stock options and ends with 536,032 shares - Stock Titan
VR Adviser Adds Over 1 Million Savara Shares - AOL.com
Will Advancing MOLBREEVI and a New HQ Lease Change Savara's (SVRA) Narrative? - simplywall.st
Savara grants inducement equity awards to new employee - MSN
Weekly Earnings: Can Savara Inc withstand a market correctionGDP Growth & Proven Capital Preservation Tips - baoquankhu1.vn
FY2026 Earnings Estimate for Savara Issued By HC Wainwright - MarketBeat
Lifesci Capital Analysts Lift Earnings Estimates for Savara - MarketBeat
HC Wainwright Comments on Savara's Q1 Earnings (NASDAQ:SVRA) - MarketBeat
Savara says FDA review of MOLBREEVI to proceed without advisory committee - MSN
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 - MSN
Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch - streetwisereports.com
Growth Report: Will Savara Inc announce a stock splitForecast Cut & High Accuracy Swing Entry Alerts - baoquankhu1.vn
H.C. Wainwright Maintains Buy on Savara Inc. (SVRA) March 2026 - Meyka
H.C. Wainwright reiterates Savara stock rating, $10 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Savara stock rating, $10 target - Investing.com
Savara receives FDA day 74 letter for autoimmune PAP drug By Investing.com - Investing.com Nigeria
Savara Inc. $SVRA Stake Cut by Farallon Capital Management LLC - MarketBeat
VR Adviser Increases Savara Inc. Holdings in Q4 2025News and Statistics - IndexBox
Savara Says FDA Review of MOLBREEVI to Proceed Without Advisory Committee - MyChesCo
SVRA SEC FilingsSavara Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SVRASavara Inc Latest Stock News & Market Updates - Stock Titan
Savara (NASDAQ:SVRA) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Decoding Savara Inc (SVRA): A Strategic SWOT Insight - GuruFocus
Savara receives FDA priority review for rare lung disease drug By Investing.com - Investing.com South Africa
Savara Inc. 2025 Annual Report: MOLBREEVI Clinical Progress, Business Strategy, and Key Risk Factors - Minichart
Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - BioSpace
Savara (SVRA) Advances with MOLBREEVI, Boosting Financial Positi - GuruFocus
Savara Signs Long-Term Lease for New Headquarters - TipRanks
Savara (NASDAQ: SVRA) details new Yardley headquarters lease terms - Stock Titan
SVRA: Regulatory progress and robust cash position set the stage for a potential 2026 launch - TradingView
Savara receives FDA priority review for rare lung disease drug - Investing.com
Savara : Corporate Presentation - marketscreener.com
Earnings Flash (SVRA) Savara Posts Q4 Loss $0.13 a Share, vs. FactSet Est of $0.12 Loss - marketscreener.com
Savara Q4 net loss widens as expenses rise - TradingView
Savara 10-K: $0M Revenue, $0.00 EPS; $118.8M Net Loss - TradingView
SVRA: Net loss increased to $118.8M in 2025 as MOLBREEVI advanced toward FDA review and commercialization - TradingView
MOLBREEVI strategy and FDA Priority Review drive Savara (NASDAQ: SVRA) - Stock Titan
BRIEF-Savara Q4 Net Income USD -32.236 Million - TradingView
Rosalind Advisors Inc. Has $14.28 Million Position in Savara Inc. $SVRA - MarketBeat
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):